Continuing connected transactions - renewal of the meinian cooperation framework agreement and the dr. yu cooperation framework agreement
Filed with HKEX · Stock code 6667 · · 17 pages · English
Summary by 6ix AI
Mega Genomics Limited has filed a document regarding the renewal of the Meinian Cooperation Framework Agreement and the Dr. Yu Cooperation Framework Agreement, which are continuing connected transactions with controlling shareholders. The agreements outline the provision of testing services and related products to Meinian OneHealth and Dr. Yu, with proposed annual caps for the transactions over the next few years. The filing also discusses the implications under listing rules, including the need for independent shareholder approval due to the nature of the transactions. The company has established an Independent Board Committee to advise on the agreements and ensure compliance with regulatory requirements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Mega Genomics
- Next Day Disclosure Returns
- Monthly return of equity issuer on movements in securities for the month ended 31 October 2026
- Continuing connected transactions - proposed revision of the 2026 annual cap under the 2024 meinian framework agreement
Later from Mega Genomics
- Supplemental announcement in relation to the interim results for the six months ended 30 June 2026
- Continuing connected transactions - proposed revision of the 2026 annual cap under the 2024 meinian framework agreement and notice of extraordinary general meeting
- Notice of extraordinary general meeting
- Form of proxy for the extraordinary general meeting to be held on 27 November 2026
- Documents on Display
Follow Mega Genomics into a list and get an email when it puts out news.
Follow Mega Genomics